Skip to content

Clinical effect of lidocaine mucilage combined with hydromorphone on prevention of catheter-related bladder discomfort in male patients during recovery period of general anesthesia

Clinical effect of lidocaine mucilage combined with hydromorphone on prevention of catheter-related bladder discomfort in male patients during recovery period of general anesthesia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056286
Enrollment
Unknown
Registered
2022-02-03
Start date
2022-01-24
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

catheter-related bladder discomfort

Interventions

group C:During urethral catheterization, 10ml paraffin oil was applied evenly on the urethral catheter, and 5ml physiological saline was injected intravenously 30min before the operation.
group L:During urethral catheterization, 10ml lidocaine mucilage paste was applied evenly on the urethral catheter, and 5ml normal saline was injected intravenously 30min before the operation .
group LH:During urethral catheterization, 10ml lidocaine mucilage paste was applied evenly on the urethral catheter, and 10µg/kg hydromorphone was injected intravenously 30min before the operation, di

Sponsors

Xuzhou Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Ages 18-60; ASA1-2; BMI 20-27 kg /m2; Male.

Exclusion criteria

Exclusion criteria: A history of catheter placement; The presence of urinary diseases (urethral stricture, urethral injury, overactive bladder: nocturia > 3 times or urination > 8 times within 24 hours); Severe abnormality of liver and kidney function; Severe hypertension; Mental and neurological diseases; Bronchial asthma, bronchiectasis, chronic obstructive pulmonary disease; Long-term use of opioid analgesics or psychotropic drugs.

Design outcomes

Primary

MeasureTime frame
Ramsay sedation scores;CRBD incidence and severity scores;

Secondary

MeasureTime frame
Nausea;Vomit;Respiratory depression;Restlessness;

Countries

China

Contacts

Public ContactJing Cao

Xuzhou Central Hospital

beckland@163.com+86 181 1200 0290

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026